肠道菌群在肝脏疾病中的作用

王丹丹; 宋佳; 张晓岚

doi:10.3969/j.issn.1001-5256.2019.09.053

肠道菌群在肝脏疾病中的作用

DOI: 10.3969/j.issn.1001-5256.2019.09.053

河北医科大学第二医院东院区消化内科

详细信息

中图分类号: R575
计量
- 文章访问数: 625
- HTML全文浏览量: 66
- PDF下载量: 832
- 被引次数: 0
出版历程
- 收稿日期: 2019-04-17
- 出版日期: 2019-09-20

Research advances in the role of gut microbiota in liver diseases

Department of Gastroenterology, The East Branch of The Second Hospital of Hebei Medical University

摘要

摘要: 肠道菌群失调是肝脏疾病的重要致病因素。肠道和肝脏之间存在相互联系、相互作用的肠-肝轴。肝脏是人体重要的免疫器官,其通过门静脉暴露于肠道细菌及其代谢产物后,激活天然免疫和适应性免疫系统,从而引发肝损伤。作为肠-肝轴的重要组成部分,肠道菌群既是肝脏疾病的促发因素,又是潜在的治疗靶点。阐述了肠道菌群与多种肝脏疾病的关系,认为应深入探究肠道菌群及其代谢产物在肝脏疾病中的作用机制,明确肠-肝轴的病理生理作用,为肝脏疾病的防治提供依据。
- 肝疾病 /
- 胃肠道微生物组 /
- 肠-肝轴
Abstract: Intestinal dysbacteriosis is an important pathogenic factor for liver diseases. There exists a gut-liver axis between the gut and the liver, which helps with the interactions between these two organs. The liver is an important immune organ, and after being exposed to intestinal bacteria and their metabolites via the portal vein, the liver may activate innate immunity and adaptive immunity, which may lead to liver injury. As an important component of the gut-liver axis, gut microbiota is not only a triggering factor but also a potential therapeutic target for liver diseases. This article elaborates on the association between gut microbiota and liver diseases and points out that in-depth studies should be performed to explore the mechanism of action of gut microbiota and their metabolites in liver disease and further clarify the physiopathological role of gut-liver axis, in order to provide a basis for the prevention and treatment of liver diseases.
- liver diseases /
- gastrointestinal microbiome /
- gut-liver axis

HTML全文

参考文献(36)

[1] MILOSEVIC I, VUJOVIC A, BARAC A, et al. Gut-liver axis, gut microbiota, and its modulation in the management of liver diseases:A review of the literature[J]. Int J Mol Sci, 2019, 20 (2) :e395.

[2]LVAREZ-MERCADO AI, NAVARRO-OLIVEROS M, ROBLES-SNCHEZ C, et al. Microbial population changes and their relationship with human health and disease[J]. Microorganisms, 2019, 7 (3) :e68.

[3] KHO ZY, LAL SK. The human gut microbiome-a potential controller of wellness and disease[J]. Front Microbiol, 2018, 9:1835.

[4] CHOU HH, CHIEN WH, WU LL, et al. Age-related immune clearance of hepatitis B virus infection requires the establishment of gut microbiota[J]. Proc Natl Acad Sci U S A, 2015, 112 (7) :2175-2180.

[5] KANG Y, CAI Y. Gut microbiota and hepatitis-B-virus-induced chronic liver disease:Implications for faecal microbiota transplantation therapy[J]. J Hosp Infect, 2017, 96 (4) :342-348.

[6] REN YD, YE ZS, YANG LZ, et al. Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBe Ag) clearance in patients with positive HBe Ag after long-term antiviral therapy[J]. Hepatology, 2017, 65 (5) :1765-1768.

[7] INOUE T, NAKAYAMA J, MORIYA K, et al. Gut dysbiosis associated with hepatitis C virus infection[J]. Clin Infect Dis, 2018, 67 (6) :869-877.

[8] LI F, SUN G, WANG Z, et al. Characteristics of fecal microbiota in non-alcoholic fatty liver disease patients[J]. Sci China Life Sci, 2018, 61 (7) :770-778.

[9] BRANDL K, SCHNABL B. Intestinal microbiota and nonalcoholic steatohepatitis[J]. Curr Opin Gastroenterol, 2017, 33 (3) :128-133.

[10] BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J].Hepatology, 2016, 63 (3) :764-775.

[11] SAFARI Z, GRARD P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD) [J]. Cell Mol Life Sci, 2019, 76 (8) :1541-1558.

[12] MA J, ZHOU Q, LI H. Gut microbiota and nonalcoholic fatty liver disease:Insights on mechanisms and therapy[J]. Nutrients, 2017, 9 (10) :e1124.

[13] BOMHOF MR, PARNELL JA, RAMAY HR, et al. Histological improvement of non-alcoholic steatohepatitis with a prebiotic:A pilot clinical trial[J]. Eur J Nutr, 2018, 58 (4) :1735-1745.

[14] KHALESI S, JOHNSON DW, CAMPBELL K, et al. Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes:A systematic review and meta-analysis[J]. Eur J Nutr, 2018, 57 (6) :2037-2053.

[15] MENG X, LI S, LI Y, et al. Gut microbiota's relationship with liver disease and role in hepatoprotection by dietary natural products and probiotics[J]. Nutrients, 2018, 10 (10) :e1457.

[16] CASSARD AM, CIOCAN D. Microbiota, a key player in alcoholic liver disease[J]. Clin Mol Hepatol, 2018, 24 (2) :100-107.

[17] STRKEL P, LECLERCQ S, de TIMARY P, et al. Intestinal dysbiosis and permeability:The yin and yang in alcohol dependence and alcoholic liver disease[J]. Clin Sci (Lond) , 2018, 132 (2) :199-212.

[18] LLOPIS M, CASSARD AM, WRZOSEK L, et al. Intestinal microbiota contributes to individual susceptibility to alcoholic liver disease[J]. Gut, 2016, 65 (5) :830-839.

[19] KONTUREK PC, HARSCH IA, KONTUREK K, et al. Gut-liver axis:How do gut bacteria influence the liver?[J]. Med Sci (Basel) , 2018, 6 (3) :e79.

[20] LI F, DUAN K, WANG C, et al. Probiotics and alcoholic liver disease:Treatment and potential mechanisms[J]. Gastroenterol Res Pract, 2016, 2016:5491465.

[21] PHILIPS CA, PHADKE N, GANESAN K, et al. Healthy donor faecal transplant for corticosteroid non-responsive severe alcoholic hepatitis[J]. BMJ Case Rep, 2017. pii:bcr-2017-222310.

[22] ZHANG X, WANG H, YIN P, et al. Flaxseed oil ameliorates alcoholic liver disease via anti-inflammation and modulating gut microbiota in mice[J]. Lipids Health Dis, 2017, 16 (1) :44.

[23] MATTNER J. Impact of microbes on the pathogenesis of primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC) [J]. Int J Mol Sci, 2016, 17 (11) :e1864.

[24] TANG R, WEI Y, LI Y, et al. Gut microbial profile is altered in primary biliary cholangitis and partially restored after UDCA therapy[J]. Gut, 2018, 67 (3) :534-541.

[25] WEI X, ZHAO JT, JIA XD, et al. Abnormal gut microbiota metabolism specific for liver cirrhosis[J]. Front Microbiol, 2018, 9:3051.

[26] GOEL A, RAHIM U, NGUYEN LH, et al. Systematic review with meta-analysis:Rifaximin for the prophylaxis of spontaneous bacterial peritonitis[J]. Aliment Pharmacol Ther, 2017, 46 (11-12) :1029-1036.

[27] KIMER N, PEDERSEN JS, BUSK TM, et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis:A randomized, double-blind, placebo-controlled trial[J]. Hepatology, 2017, 65 (2) :592-603.

[28] KIMER N, PEDERSEN JS, TAVENIER J, et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis:A randomized trial[J]. J Gastroenterol Hepatol, 2018, 33 (1) :307-314.

[29] CAO Q, YU CB, YANG SG, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy:A meta-analysis[J]. Hepatobiliary Pancreat Dis Int, 2018, 17 (1) :9-16.

[30] ALTAMIRANO-BARRERA A, URIBE M, CHVEZ-TAPIA NC, et al. The role of the gut microbiota in the pathology and prevention of liver disease[J]. J Nutr Biochem, 2018, 60:1-8.

[31] BAJAJ JS, KASSAM Z, FAGAN A, et al. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy:A randomized clinical trial[J]. Hepatology, 2017, 66 (6) :1727-1738.

[32] PONZIANI FR, BHOORI S, CASTELLI C, et al. Hepatocellular carcinoma is associated with gut microbiota profile and inflammation in nonalcoholic fatty liver disease[J]. Hepatology, 2019, 69 (1) :107-120.

[33] MA C, HAN M, HEINRICH B, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells[J]. Science, 2018, 360 (6391) . pii:eaan5931.

[34] HOU J, LU Y, ZHANG DK. Association between intestinal dysbacteriosis and liver diseases[J]. J Clin Hepatol, 2018, 34 (5) :1128-1132. (in Chinese) 侯静, 路越, 张德凯.肠道菌群失调与肝脏疾病的关系[J].临床肝胆病杂志, 2018, 34 (5) :1128-1132.

[35] HUANG R, NI JJ, GAO Y. The association between the intestinal microbiota-lipopolysaccharide-Toll-like receptor 4 axis and hepatocellular carcinoma[J]. J Clin Hepatol, 2018, 34 (6) :1325-1328. (in Chinese) 黄蓉, 倪加加, 高毅.肠道菌群-脂多糖-Toll样受体4轴与肝细胞癌的关系[J].临床肝胆病杂志, 2018, 34 (6) :1325-1328.

[36] LI J, SUNG CY, LEE N, et al. Probiotics modulated gut microbiota suppresses hepatocellular carcinoma growth in mice[J].Proc Natl Acad Sci U S A, 2016, 113 (9) :e1306-e1315.

施引文献

资源附件(0)

访问统计